Key result
Anthocyanin supplementation had no significant effect on IL-1β, TNF-α, or IL-6 levels in patients with metabolic disorders.
Why the study?
Patients with metabolic disorders benefit from anthocyanins, but findings from extant trials regarding their effect on inflammatory biomarkers remain contentious.
Does anthocyanin supplementation reduce pro-inflammatory biomarkers in patients with metabolic disorders?
Meta-Analysis
Does anthocyanin supplementation reduce pro-inflammatory biomarkers in patients with metabolic disorders?
Anthocyanin supplementation does not significantly reduce pro-inflammatory biomarkers in patients with metabolic disorders, and the observed effect sizes are not clinically important.
Answers are grounded in this paper and cite their sources.
Anthocyanins show no significant effect on inflammatory biomarkers in metabolic disorders; challenges prior positive reports and redirects research toward established therapies.
Patients with metabolic disorders benefit from using anthocyanins. Nevertheless, the findings drawn from extant trials remain contentious. Thus, this meta-analysis evaluated anthocyanin's effect on inflammatory biomarkers in patients with metabolic disorders. We comprehensively searched electronic databases, including PubMed, Scopus, Web of Science, and CENTRAL, from their inception to June 14, 2024. A total of 11 randomized controlled clinical trials with 14 arms were analyzed. There was no significant effect of anthocyanin supplementation on interleukin (IL)-1β levels (standardized mean difference [SMD] = –0.01, 95% CI: –0.33, 0.31; P = 0.941, I 2 = 62.4%, P = 0.031), tumor necrosis factor-α (TNF-α) (SMD = –0.49, 95% CI: –1.07, 0.09; P = 0.098, I 2 = 94.0%, P < 0.001) and IL-6 (SMD = –0.69, 95% CI: –1.45, 0.06; P = 0.073, I 2 = 95.2%, P < 0.001), respectively. A significant between-study heterogeneity was identified, which was reduced when subgrouping by sample size, dosage, and study population. However, subgroup analysis showed that it might decrease TNF-α and IL-6 in patients with hypertension, and if the intervention lasted less than 12 weeks. There was no significant impact of anthocyanin supplementation on IL-1β, TNF-α, and IL-6; however, it should be noted that the intervention has a decreasing impact on individuals with hypertension. Our observed effect sizes on IL-1β, TNF-α, and IL-6 are not clinically important.
No takes yet. Share an insight, caveat, or question.
Kiadehi et al. (2024) conducted a meta-analysis in Metabolic disorders. Anthocyanin supplementation vs. Control was evaluated on Interleukin (IL)-1β levels (SMD -0.01, 95% CI -0.33, 0.31, p=0.941). Anthocyanin supplementation had no significant effect on IL-1β, TNF-α, or IL-6 levels in patients with metabolic disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: